Bionime Corporation (4737.TW)
TWD 55.6
(-3.47%)
TWD 55.6
(-3.47%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 5.3 Billion TWD | 6.37% |
| 2022 | 4.98 Billion TWD | 9.18% |
| 2021 | 4.56 Billion TWD | 1.76% |
| 2020 | 4.48 Billion TWD | 1.83% |
| 2019 | 4.4 Billion TWD | -4.03% |
| 2018 | 4.58 Billion TWD | 4.9% |
| 2017 | 4.37 Billion TWD | -5.85% |
| 2016 | 4.64 Billion TWD | 1.74% |
| 2015 | 4.56 Billion TWD | -2.14% |
| 2014 | 4.66 Billion TWD | 3.16% |
| 2013 | 4.52 Billion TWD | 24.56% |
| 2012 | 3.63 Billion TWD | 27.4% |
| 2011 | 2.85 Billion TWD | 121.51% |
| 2010 | 1.28 Billion TWD | 44.28% |
| 2009 | 892.08 Million TWD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 5.42 Billion TWD | 2.12% |
| 2024 Q1 | 5.31 Billion TWD | 0.2% |
| 2023 Q3 | 5.08 Billion TWD | 1.49% |
| 2023 FY | 5.3 Billion TWD | 6.37% |
| 2023 Q1 | 4.94 Billion TWD | -0.71% |
| 2023 Q2 | 5 Billion TWD | 1.2% |
| 2023 Q4 | 5.3 Billion TWD | 4.31% |
| 2022 Q3 | 4.93 Billion TWD | -0.5% |
| 2022 FY | 4.98 Billion TWD | 9.18% |
| 2022 Q4 | 4.98 Billion TWD | 0.88% |
| 2022 Q2 | 4.96 Billion TWD | 3.49% |
| 2022 Q1 | 4.79 Billion TWD | 5.11% |
| 2021 Q1 | 4.51 Billion TWD | 0.61% |
| 2021 FY | 4.56 Billion TWD | 1.76% |
| 2021 Q3 | 4.55 Billion TWD | 2.2% |
| 2021 Q4 | 4.56 Billion TWD | 0.1% |
| 2021 Q2 | 4.46 Billion TWD | -1.13% |
| 2020 Q1 | 4.3 Billion TWD | -2.3% |
| 2020 Q4 | 4.48 Billion TWD | -0.26% |
| 2020 FY | 4.48 Billion TWD | 1.83% |
| 2020 Q2 | 4.42 Billion TWD | 2.74% |
| 2020 Q3 | 4.49 Billion TWD | 1.72% |
| 2019 Q2 | 4.36 Billion TWD | -1.8% |
| 2019 Q4 | 4.4 Billion TWD | -0.1% |
| 2019 FY | 4.4 Billion TWD | -4.03% |
| 2019 Q1 | 4.44 Billion TWD | -3.14% |
| 2019 Q3 | 4.4 Billion TWD | 0.99% |
| 2018 Q4 | 4.58 Billion TWD | 6.75% |
| 2018 FY | 4.58 Billion TWD | 4.9% |
| 2018 Q3 | 4.29 Billion TWD | 3.34% |
| 2018 Q2 | 4.16 Billion TWD | -3.52% |
| 2018 Q1 | 4.31 Billion TWD | -1.43% |
| 2017 Q3 | 4.49 Billion TWD | 2.51% |
| 2017 Q2 | 4.38 Billion TWD | -0.25% |
| 2017 Q1 | 4.39 Billion TWD | -5.46% |
| 2017 FY | 4.37 Billion TWD | -5.85% |
| 2017 Q4 | 4.37 Billion TWD | -2.6% |
| 2016 Q3 | 4.39 Billion TWD | -3.0% |
| 2016 Q4 | 4.64 Billion TWD | 5.78% |
| 2016 FY | 4.64 Billion TWD | 1.74% |
| 2016 Q1 | 4.37 Billion TWD | -4.11% |
| 2016 Q2 | 4.52 Billion TWD | 3.4% |
| 2015 Q1 | 4.02 Billion TWD | -13.77% |
| 2015 Q2 | 4.1 Billion TWD | 1.98% |
| 2015 Q3 | 4.12 Billion TWD | 0.54% |
| 2015 FY | 4.56 Billion TWD | -2.14% |
| 2015 Q4 | 4.56 Billion TWD | 10.69% |
| 2014 Q3 | 4.4 Billion TWD | 0.06% |
| 2014 Q1 | 4.33 Billion TWD | -4.2% |
| 2014 FY | 4.66 Billion TWD | 3.16% |
| 2014 Q4 | 4.66 Billion TWD | 6.03% |
| 2014 Q2 | 4.39 Billion TWD | 1.5% |
| 2013 FY | 4.52 Billion TWD | 24.56% |
| 2013 Q3 | 4.33 Billion TWD | 6.67% |
| 2013 Q4 | 4.52 Billion TWD | 4.45% |
| 2013 Q1 | 3.85 Billion TWD | 6.14% |
| 2013 Q2 | 4.06 Billion TWD | 5.33% |
| 2012 Q1 | 3.64 Billion TWD | 27.95% |
| 2012 FY | 3.63 Billion TWD | 27.4% |
| 2012 Q4 | 3.63 Billion TWD | 0.39% |
| 2012 Q3 | 3.61 Billion TWD | -1.64% |
| 2012 Q2 | 3.67 Billion TWD | 0.85% |
| 2011 Q1 | 1.52 Billion TWD | 18.23% |
| 2011 Q4 | 2.85 Billion TWD | -4.21% |
| 2011 FY | 2.85 Billion TWD | 121.51% |
| 2011 Q3 | 2.97 Billion TWD | 73.22% |
| 2011 Q2 | 1.71 Billion TWD | 12.92% |
| 2010 FY | 1.28 Billion TWD | 44.28% |
| 2010 Q4 | 1.28 Billion TWD | 0.0% |
| 2009 FY | 892.08 Million TWD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Nang Kuang Pharmaceutical Co., Ltd. | 3.85 Billion TWD | -37.457% |
| Maxigen Biotech Inc. | 1.49 Billion TWD | -255.032% |
| SciVision Biotech Inc. | 2.16 Billion TWD | -145.378% |
| Pegavision Corporation | 13.85 Billion TWD | 61.753% |
| Visco Vision Inc. | 4.72 Billion TWD | -12.206% |